Q-omics provides the consensus-scored CLYBL profile across patient tissues and cancer cell-line models. CLYBL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLYBL is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CLYBL protein abundance shows 19,098 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where CLYBL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLYBL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLYBL survival associations across molecular data types. CLYBL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLYBL RNA expression–survival associations across cancer types. High CLYBL expression shows unfavorable associations in UVM, but favorable associations in KIRC, KIRP, MESO, COAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLYBL RNA expression.
This table summarizes CLYBL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CLYBL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLYBL shows lower tumor expression in THCA, KIRP, BLCA, HNSC, KIRC and COAD. The THCA box plot shows higher CLYBL RNA expression in normal versus tumor tissue (log2 FC = −1.245, t-test p < 0.001).
This table shows molecular features associated with CLYBL in patient tissues and cancer cell lines. In patient samples, CLYBL shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLYBL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
